Dyne Therapeutics (NASDAQ:DYN) Given “Outperform” Rating at Oppenheimer

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “outperform” rating reissued by analysts at Oppenheimer in a report released on Monday, Benzinga reports. They presently have a $47.00 target price on the stock. Oppenheimer’s price objective suggests a potential upside of 83.24% from the stock’s previous close.

DYN has been the topic of a number of other reports. Chardan Capital reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Dyne Therapeutics in a report on Monday. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 3rd. Piper Sandler lifted their price objective on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Morgan Stanley began coverage on shares of Dyne Therapeutics in a report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price objective for the company. Finally, Stifel Nicolaus raised their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.75.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $25.65 on Monday. The stock has a market cap of $2.24 billion, a PE ratio of -6.46 and a beta of 1.00. The firm has a 50-day moving average of $26.47 and a 200-day moving average of $18.83. Dyne Therapeutics has a 52-week low of $6.40 and a 52-week high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.17). As a group, analysts predict that Dyne Therapeutics will post -3.27 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, COO Susanna Gatti High sold 2,292 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $25.70, for a total value of $58,904.40. Following the sale, the chief operating officer now directly owns 156,800 shares of the company’s stock, valued at $4,029,760. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Joshua T. Brumm sold 5,520 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $27.50, for a total value of $151,800.00. Following the completion of the transaction, the chief executive officer now directly owns 563,471 shares in the company, valued at approximately $15,495,452.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Susanna Gatti High sold 2,292 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $25.70, for a total value of $58,904.40. Following the sale, the chief operating officer now directly owns 156,800 shares in the company, valued at approximately $4,029,760. The disclosure for this sale can be found here. Insiders sold 1,875,432 shares of company stock worth $44,368,530 over the last three months. Insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently bought and sold shares of the company. Raymond James & Associates grew its holdings in shares of Dyne Therapeutics by 22.6% during the third quarter. Raymond James & Associates now owns 88,238 shares of the company’s stock worth $791,000 after purchasing an additional 16,240 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Dyne Therapeutics by 4.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 157,443 shares of the company’s stock worth $1,411,000 after buying an additional 7,196 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Dyne Therapeutics by 58.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after acquiring an additional 3,092 shares during the last quarter. TD Asset Management Inc acquired a new position in Dyne Therapeutics in the 3rd quarter valued at approximately $206,000. Finally, Allspring Global Investments Holdings LLC increased its position in Dyne Therapeutics by 95.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock valued at $83,000 after acquiring an additional 4,552 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.